Coronavirus disease-19 (COVID-19) has caused great challenges for antibiotic stewardship teams (AST).

Drug use evaluation data combined with a driver analysis can help AST to target their interventions.

Assessing the quantity and quality of antibiotics prescribed for a (presumed) bacterial respiratory tract infection is an essential part of evaluating prescribing practice in an objective manner.

The diagnosis of bacterial respiratory tract infections in patients with COVID-19 is difficult.

In order to facilitate surveillance of antibiotic prescribing and decrease the risk of antimicrobial resistance, accurate diagnostic markers and infection control are complementary to prescribing data.